GRANIX

6 ADVERSE REACTIONS The following potential serious adverse reactions are discussed in greater detail in other sections of the labeling: Fatal Splenic Rupture [see Warnings and Precautions (5.1) ] Acute Respiratory Distress Syndrome [see Warnings and Precautions (5.2) ] Serious Allergic Reactions [see Warnings and Precautions (5.3) ] Sickle Cell Disorders [see Warnings and Precautions (5.4) ] Glomerulonephritis [see Warnings and Precautions (5.5) ] Capillary Leak Syndrome [see Warnings and Precautions (5.6) ] Potential for Tumor Growth Stimulatory Effects on Malignant Cells [see Warnings and Precautions (5.7) ] Leukocytosis [ see Warnings and Precautions ( 5.8 ) ] Simultaneous Use with Chemotherapy and Radiation Therapy Not Recommended [see Warnings and Precautions ( 5.9 ) ] Aortitis [see Warnings and Precautions ( 5.11 ) ] Most common adverse reaction (≥1%) to GRANIX is bone pain ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1 ‑ 866-832-8537 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Adverse Reactions in Adult Patients GRANIX clinical trials safety data are based upon the results of three randomized clinical trials in patients receiving myeloablative chemotherapy for breast cancer (N=348), lung cancer (N=240) and non-Hodgkin’s lymphoma (N=92). In the breast cancer study, 99% of patients were female, the median age was 50 years, and 86% of patients were Caucasian. In the lung cancer study, 80% of patients were male, the median age was 58 years, and 95% of patients were Caucasian. In the non-Hodgkin’s lymphoma study, 52% of patients were male, the median age was 55 years, and 88% of patients were Caucasian. In all three studies a placebo (Cycle 1 of the breast cancer study only) or a non-US-approved filgrastim product were used as controls. Both GRANIX and the non-US-approved filgrastim product were administered at 5 mcg/kg subcutaneously once daily beginning one day after chemotherapy for at least five days and continued to a maximum of 14 days or until an ANC of ≥10,000 x 10 6 /L after nadir was reached. Bone pain was the most frequent treatment-emergent adverse reaction that occurred in at least 1% or greater in patients treated with GRANIX at the recommended dose and was numerically two times more frequent than in the placebo group. The overall incidence of bone pain in Cycle 1 of treatment was 3.4% (3.4% GRANIX, 1.4% placebo, 7.5% non-US-approved filgrastim product). Leukocytosis In clinical studies, leukocytosis (WBC counts > 100,000 x 10 6 /L) was observed in less than 1% patients with non-myeloid malignancies receiving GRANIX. No complications attributable to leukocytosis were reported in clinical studies. Additional Adverse Reactions Other adverse reactions known to occur following administration of filgrastim products include myalgia, headache, vomiting, cutaneous vasculitis and thrombocytopenia. Adverse Reactions in Pediatric Patients GRANIX clinical trials safety data in pediatric patients are based upon the results of one single-arm clinical trial in 50 pediatric patients who received myelosuppressive chemotherapy for treatment of solid tumors without marrow involvement [see Use in Special Populations (8.4)] . In this study, GRANIX was administered at 5 mcg/kg subcutaneously once daily beginning one day after chemotherapy. The most common (>5%) adverse reactions included thrombocytopenia (34%), pyrexia (8%), pain in extremity (6%), headache (6%) and diarrhea (6%). 6.2 Immunogenicity As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay, and the observed incidence of antibody positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to GRANIX with the incidence of antibodies to other products may be misleading. Binding antibodies to GRANIX were detected using a validated bridging immunoassay. Anti-drug antibodies to tbo-filgrastim occurred in 1.4 % of 486 adult and pediatric patients. None of these patients had cross-reactive antibodies to the native G-CSF. All antibody responses were transient and of low titers. 6.3 Postmarketing Experience The following adverse reactions have been identified during post-approval use of GRANIX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Sweet’s syndrome (acute febrile neutrophilic dermatosis), asthenia, diarrhea, and fatigue

4 CONTRAINDICATIONS GRANIX is contraindicated in patients with a history of serious allergic reactions to filgrastim products or pegfilgrastim products [ see Warnings and Precautions (5.3) ]. Patients with a history of serious allergic reactions to filgrastim products or pegfilgrastim products. ( 4 )

11 DESCRIPTION GRANIX (tbo-filgrastim) is a non-glycosylated recombinant methionyl human granulocyte colony-stimulating growth factor (r-metHuG-CSF) manufactured by recombinant DNA technology using the bacterium strain E coli K802. It has a molecular weight of approximately 18.8 kDa and is composed of 175 amino acids. The endogenous human G-CSF is glycosylated and does not have the additional methionine amino acid residue in its NH 2 terminal end. The product is a sterile, clear, colorless, preservative-free solution containing tbo-filgrastim, glacial acetic acid, sorbitol, polysorbate 80, sodium hydroxide, and Water for Injection. The product is available in single-dose prefilled syringes that contain either 300 mcg or 480 mcg of tbo-filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively and single-dose vials that contain either 300 mcg or 480 mcg of tbo-filgrastim at a fill volume of 1 mL or 1.6 mL, respectively. See table below for product composition of each presentation. Product Composition 300 mcg/0.5 mL Syringe 480 mcg/0.8 mL Syringe 300 mcg/1mL Vial 480 mcg/1.6 mL Vial Tbo-filgrastim 300 mcg 480 mcg 300 mcg 480 mcg Glacial Acetic Acid 0.3 mg 0.48 mg 0.6 mg 0.96 mg Polysorbate 80 0.0275 mg 0.044 mg 0.055 mg 0.088 mg Sorbitol 25 mg 40 mg 50 mg 80 mg Sodium Hydroxide q.s. to pH 4.2 q.s. to pH 4.2 q.s. to pH 4.2 q.s. to pH 4.2 Water for Injection q.s. to 0.5 mL q.s. to 0.8 mL q.s. to 1.0 mL q.s. to 1.6 mL q.s. = quantity sufficient to make

2 DOSAGE AND ADMINISTRATION Recommended dose: 5 mcg/kg per day administered as a subcutaneous injection. Administer the first dose no earlier than 24 hours following myelosuppressive chemotherapy. Do not administer within 24 hours prior to chemotherapy ( 2.1 ) 2.1 Dosage The recommended dose of GRANIX is 5 mcg/kg per day administered as a subcutaneous injection. Administer the first dose of GRANIX no earlier than 24 hours following myelosuppressive chemotherapy. Do not administer GRANIX within 24 hours prior to chemotherapy. Daily dosing with GRANIX should continue until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range. Monitor complete blood count (CBC) prior to chemotherapy and twice per week until recovery. 2.2 General Considerations for Administration GRANIX may be administered by either a healthcare professional, a patient or caregiver. Before a decision is made to allow GRANIX to be administered by a patient or caregiver, ensure that the patient is an appropriate candidate for self-administration or administration by a caregiver. Proper training on storage, preparation, and administration technique should be provided. If a patient or caregiver is not an appropriate candidate for any reason, then in such patients, GRANIX should be administered by a healthcare professional. Dispense only the pre-filled syringe without a safety needle guard device to patient or caregiver. Instruct patients and caregivers to follow the Instructions for Use provided with the GRANIX prefilled syringe to properly administer an injection after training by a healthcare professional. Visually inspect parenteral drug products for particulate matter and discoloration prior to administration. Do not administer GRANIX if discoloration or particulates are observed. The prefilled syringe and vial are for single-dose only. Discard unused portions. GRANIX and all its components are not made with natural rubber latex. Recommended sites for subcutaneous GRANIX injections include the abdomen (except for the two-inch area around the navel), the front of the middle thighs, the upper outer areas of the buttocks, or the upper back portion of the upper arms. The injection site should be varied daily. GRANIX should not be injected into an area that is tender, red, bruised, or hard, or that has scars or stretch marks. 2.3 Instructions for Use of the Safety Needle Guard Device by Healthcare Professionals Hold the syringe assembly by the open sides of the device and remove the needle shield. Expel any extra volume depending on dose needed. Inject GRANIX subcutaneously as recommended [ see Dosage and Administration (2.2) ]. Push the plunger as far as it will go to inject all the medication. Injection of the entire prefilled syringe contents is necessary to activate the needle guard. With the plunger still pressed all the way down, remove the needle from the skin. Slowly let go of the plunger and allow the empty syringe to move up inside the device until the entire needle is guarded. Discard the syringe assembly in approved containers. needle image 1 needle image 2 needle image 3 needle image 4 needle image 5 needle image 6

1 INDICATIONS AND USAGE GRANIX is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. GRANIX (tbo-filgrastim) is a leukocyte growth factor indicated in adult and pediatric patients 1 month and older for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1 )

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tbo-filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Tbo-filgrastim binds to G-CSF receptors and stimulates proliferation of neutrophils. G-CSF is known to stimulate differentiation commitment and some end-cell functional activation, which increases neutrophil counts and activity. 12.2 Pharmacodynamics The time to the maximum ANC level was between 3 to 5 days and returned to baseline by 21 days following completion of chemotherapy. Doubling the tbo-filgrastim subcutaneous dose from 5 mcg/kg to 10 mcg/kg resulted in a 16% to 19% increase in the maximum ANC level and a 33% to 36% increase in the area under the effect curve for ANC. Cardiac Electrophysiology At an intravenous dose of 5 mcg/kg, tbo-filgrastim did not prolong the QT interval to any clinically relevant extent. 12.3 Pharmacokinetics Tbo-filgrastim exhibits nonlinear pharmacokinetics. Increasing the dose of subcutaneous GRANIX from 5 to 10 mcg/kg resulted in an approximate 2.5-fold increase in the maximum serum concentration (C max ) and 3.0-fold increase in the area under the curve (AUC). In adult patients enrolled across three studies, subcutaneous GRANIX 5 mcg/kg resulted in median time to maximal serum tbo-filgrastim concentrations (T max ) within 4 to 6 hours. Geometric mean [coefficient of variation (CV%)] serum Cmax was 20 to 31 ng/mL [24% to 65%] within 4 to 6 hours. Geometric mean serum tbo-filgrastim area under the curve (AUC 0-12h ) ranged from 151 to 227 ng/mL*h [24%-60%]. No accumulation in serum tbo-filgrastim concentrations was observed after multiple dosing. Absorption The absolute bioavailability of 5 mcg/kg subcutaneous tbo-filgrastim was 33%. Metabolism/Elimination Tbo-filgrastim clearance is primarily dependent on G-CSF receptor-mediated clearance which can be saturated by high serum concentrations of tbo-filgrastim and diminished in neutropenia. The median serum elimination half-life of tbo-filgrastim (5 mcg/kg sc) was 3.0 to 3.5 hours. Specific Populations No sex-related differences were observed. Pediatric Patients: The geometric mean [coefficient of variation (CV%)] of C max was 18 ng/mL (56%) and AUC 0-12h was 130 ng*hr/mL (52%) following subcutaneous administration of GRANIX 5 mcg/kg in 49 pediatric patients (1.4 to 15.9 years) after chemotherapy. No clinically relevant differences in the pharmacokinetics of GRANIX were observed between infants, children and adolescents. Patients with Renal or Hepatic Impairment: Mild renal impairment (creatinine clearance 60 to 89 mL/min by Cockcroft-Gault) had no effect on tbo-filgrastim pharmacokinetics. The pharmacokinetics in patients with moderate and severe renal impairment has not been studied. The pharmacokinetics in patients with hepatic impairment has not been studied.

12.1 Mechanism of Action Tbo-filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Tbo-filgrastim binds to G-CSF receptors and stimulates proliferation of neutrophils. G-CSF is known to stimulate differentiation commitment and some end-cell functional activation, which increases neutrophil counts and activity.

12.2 Pharmacodynamics The time to the maximum ANC level was between 3 to 5 days and returned to baseline by 21 days following completion of chemotherapy. Doubling the tbo-filgrastim subcutaneous dose from 5 mcg/kg to 10 mcg/kg resulted in a 16% to 19% increase in the maximum ANC level and a 33% to 36% increase in the area under the effect curve for ANC. Cardiac Electrophysiology At an intravenous dose of 5 mcg/kg, tbo-filgrastim did not prolong the QT interval to any clinically relevant extent.

12.3 Pharmacokinetics Tbo-filgrastim exhibits nonlinear pharmacokinetics. Increasing the dose of subcutaneous GRANIX from 5 to 10 mcg/kg resulted in an approximate 2.5-fold increase in the maximum serum concentration (C max ) and 3.0-fold increase in the area under the curve (AUC). In adult patients enrolled across three studies, subcutaneous GRANIX 5 mcg/kg resulted in median time to maximal serum tbo-filgrastim concentrations (T max ) within 4 to 6 hours. Geometric mean [coefficient of variation (CV%)] serum Cmax was 20 to 31 ng/mL [24% to 65%] within 4 to 6 hours. Geometric mean serum tbo-filgrastim area under the curve (AUC 0-12h ) ranged from 151 to 227 ng/mL*h [24%-60%]. No accumulation in serum tbo-filgrastim concentrations was observed after multiple dosing. Absorption The absolute bioavailability of 5 mcg/kg subcutaneous tbo-filgrastim was 33%. Metabolism/Elimination Tbo-filgrastim clearance is primarily dependent on G-CSF receptor-mediated clearance which can be saturated by high serum concentrations of tbo-filgrastim and diminished in neutropenia. The median serum elimination half-life of tbo-filgrastim (5 mcg/kg sc) was 3.0 to 3.5 hours. Specific Populations No sex-related differences were observed. Pediatric Patients: The geometric mean [coefficient of variation (CV%)] of C max was 18 ng/mL (56%) and AUC 0-12h was 130 ng*hr/mL (52%) following subcutaneous administration of GRANIX 5 mcg/kg in 49 pediatric patients (1.4 to 15.9 years) after chemotherapy. No clinically relevant differences in the pharmacokinetics of GRANIX were observed between infants, children and adolescents. Patients with Renal or Hepatic Impairment: Mild renal impairment (creatinine clearance 60 to 89 mL/min by Cockcroft-Gault) had no effect on tbo-filgrastim pharmacokinetics. The pharmacokinetics in patients with moderate and severe renal impairment has not been studied. The pharmacokinetics in patients with hepatic impairment has not been studied.

20191130

21

3 DOSAGE FORMS AND STRENGTHS GRANIX is a clear, colorless, preservative-free solution available as: Prefilled Syringe: Injection: 300 mcg/0.5 mL (600 mcg/mL) solution in single-dose prefilled syringe Injection: 480 mcg/0.8 mL (600 mcg/mL) solution in single-dose prefilled syringe Vial: Injection: 300 mcg/1 mL solution in single-dose vial Injection: 480 mcg/1.6 mL (300 mcg/mL) solution in single-dose vial Prefilled Syringe Injection: 300 mcg/0.5 mL solution in single-dose prefilled syringe ( 3 ) Injection: 480 mcg/0.8 mL solution in single-dose prefilled syringe ( 3 ) Vial Injection: 300 mcg/1 mL solution in single-dose vials ( 3 ) Injection: 480 mcg/1.6 mL solution in single-dose vials ( 3 )

GRANIX tbo-filgrastim FILGRASTIM FILGRASTIM ACETIC ACID SORBITOL POLYSORBATE 80 SODIUM HYDROXIDE WATER GRANIX tbo-filgrastim FILGRASTIM FILGRASTIM ACETIC ACID SORBITOL POLYSORBATE 80 SODIUM HYDROXIDE WATER GRANIX tbo-filgrastim FILGRASTIM FILGRASTIM ACETIC ACID SORBITOL POLYSORBATE 80 SODIUM HYDROXIDE WATER GRANIX tbo-filgrastim FILGRASTIM FILGRASTIM ACETIC ACID SORBITOL POLYSORBATE 80 SODIUM HYDROXIDE WATER

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity and genetic toxicology studies have not been conducted with tbo-filgrastim. A fertility study was not conducted with tbo-filgrastim. Toxicology studies of up to 26 weeks in rats or monkeys did not reveal findings in male or female reproductive organs that would suggest impairment of fertility.

13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity and genetic toxicology studies have not been conducted with tbo-filgrastim. A fertility study was not conducted with tbo-filgrastim. Toxicology studies of up to 26 weeks in rats or monkeys did not reveal findings in male or female reproductive organs that would suggest impairment of fertility.

BLA125294

GRANIX

tbo-filgrastim

63459-918

HUMAN PRESCRIPTION DRUG

SUBCUTANEOUS

Package/Label Display Panel 63459-910-11 NDC 63459-910-11 Rx only Granix® (tbo-filgrastim) Injection 300 mcg/0.5 mL For Subcutaneous Use Only A recombinant Granulocyte Colony-Stimulating Factor (rG-CSF) derived from E Coli 300 mcg/0.5 mL For Healthcare Professional Use Only 1 Single-dose prefilled syringe with a safety needle guard Discard unused portion 1

RECENT MAJOR CHANGES Warnings and Precautions, Alveolar Hemorrhage ( 5.12 ) 03/2019

17 PATIENT COUNSELING INFORMATION Availability of Patient Information and Instructions for Use Advise all patients and/or caregivers to read the FDA-approved Patient Information. For patients that are candidates for self-administration, assist patients and caregivers in understanding the contents of the Patient Information as well as the GRANIX Instructions for Use that are included with the product, and give them the opportunity to ask questions prior to initiating therapy. Patient Training Once it is determined that a patient is an appropriate candidate for self-administration or administration by a caregiver, instruct the patient or caregivers on the proper storage, preparation, and administration technique for GRANIX. Patients should be advised not to skip or change their dose or stop taking GRANIX without talking to their healthcare provider first. Advise the patients to read the FDA-approved Patient Information and Instructions for Use for further information. Bone Pain Bone pain is common. Analgesics such as acetaminophen or NSAIDS may be necessary [see Adverse Reactions (6.1) ] . Rupture or Enlargement of Spleen Rupture or enlargement of the spleen may occur, which may be signaled by abdominal pain, left upper quadrant pain, or left shoulder pain. Advise patients to report onset of pain in these areas to their doctor immediately [see Warnings and Precautions (5.1) ] . Dyspnea Dyspnea with or without fever, progressing to Acute Respiratory Distress Syndrome, may occur. Advise patients to report dyspnea immediately to their doctor [see Warnings and Precautions (5.2) ] . Allergic Reactions Serious allergic reactions, including anaphylaxis, rash, and urticaria: Patients should report such reactions immediately to their doctor [see Warnings and Precautions (5.3) ] . Sickle Cell Disorders In patients with sickle cell disorders, sickle cell crisis and death has occurred. Discuss the potential risks and benefits for patients with sickle cell disorders prior to the administration of GRANIX [see Warnings and Precautions (5.4) ] . Glomerulonephritis Symptoms may include swelling of the face or ankles, dark colored urine or blood in the urine, or a decrease in urine production. Advise patients to report signs or symptoms of glomerulonephritis to their physician immediately [see Warnings and Precautions (5.5) ] . Infections GRANIX is used in circumstances where the risk of infection is increased. Patients should be alert for signs of infection such as fever, redness or swelling, and should report these findings to their doctor immediately. Pregnancy Inform patients not to become pregnant while receiving GRANIX. If pregnancy occurs, advise patients of the possibility of fetal harm [see Use in Specific Populations (8.1) ] . Lactation Inform lactating women that filgrastim was detected in breast milk for up to 3 days after dosing [see Use in Specific Populations (8.2) ] . See FDA-approved Patient Labeling (Patient Information) and Instructions for Use. TBO-009 ©2014-2019 Cephalon, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. All rights reserved. Manufactured by: UAB Teva Baltics Vilnius, Lithuania U.S. License No. 1803 Distributed by: Teva Pharmaceuticals USA, Inc. North Wales, PA 19454 Product of Israel Teva logo

Instructions for Use - Syringe GRANIX (GRAN-icks) (tbo-filgrastim) injection, for subcutaneous use Important: Keep the GRANIX syringe out of the reach of children. About the GRANIX syringe Depending on the prescription that your healthcare provider gave you, you will receive a syringe that provides a dose of either 0.1mL to 0.5mL or 0.1mL to 0.8mL. If you are prescribed a dose over 0.8mL, two syringes will be required to reach your prescribed dose. Your healthcare provider will determine how many syringes and the correct dose in milliliters (mL) you will need to give based on your body weight. You should continue to give GRANIX daily until your healthcare provider informs you that your white blood cell count has returned to normal. Make sure you understand the following: How to store your syringes. How to read the syringe markings. How to adjust the amount of GRANIX in the syringe for your prescribed dose. How to prepare and give the injection. Do not shake syringes. Do not remove the needle cap until you are ready to inject. Do not re-use a syringe. The syringe is for single-use only. Your first dose of GRANIX is given at least 24 hours after you receive your chemotherapy. Do not inject GRANIX within 24 hours before your next dose of chemotherapy. Dosing schedule Inject your total daily dose 1 time each day as prescribed by your healthcare provider, starting at least 24 hours (1 day) after the end of your chemotherapy cycle. You should continue to give GRANIX daily until your white blood cell count returns to normal. How to store your GRANIX syringes Store GRANIX in the refrigerator between 36°F to 46°F (2°C to 8°C). Store GRANIX in the original carton to protect it from light. Do not shake. Take GRANIX out of the refrigerator 30 minutes before use and allow it to reach room temperature before preparing an injection. GRANIX syringes can be left at room temperature for a single period of up to 5 days, and if not used can be returned to the refrigerator. Throw away (dispose of) any GRANIX syringes that have been left at room temperature for more than 5 days. After you inject your dose, throw away (dispose of) any unused GRANIX left in the syringe. Do not save unused GRANIX in the syringe for later use. Keep GRANIX and all medicines out of the reach of children. Determining how many syringes you need for your daily dose If your prescribed daily dose is 0.5mL or less, use 1 syringe. If your prescribed daily dose is 0.8mL or less, use 1 syringe. If your prescribed daily dose is more than 0.8mL you will need to prepare 2 syringes in order to match your prescribed dose: Adjust your first syringe to 0.8mL. Adjust your second syringe to the additional amount required to make up your total prescribed dose. Make sure the amounts in both syringes add up to your prescribed dose (See the table to the right to determine how much medicine should be in each syringe). For example: If your prescribed dose is 1mL you would prepare 1 syringe with 0.8mL and a second syringe with 0.2mL. Important : When using two syringes always adjust the first syringe to 0.8mL. How to read the syringe markings What the markings on the syringe mean: The syringe is labeled in 0.1mL unit increments from 0.1mL to 0.8mL. There is a line next to each 0.1mL unit increment. To read the dose scale always hold the syringe with the needle-end facing up so that 0.1mL is at the top and 0.8mL is at the bottom. How to adjust the medicine level for your prescribed dose When setting your dose, ( See 2C ) you will line up the top edge of the grey rubber stopper with the line on the syringe scale that matches your prescribed dose. Note : The top edge of the grey rubber stopper is the edge directly below the dome at the top of the stopper. Do not use the top of the cone or the middle or lower edges of the grey stopper to measure your dose. Injection procedure (follow the steps below for each day of dosing) 1. Prepare for injection 1A Each time you inject a dose gather the following supplies: GRANIX syringe(s) Alcohol swabs Paper towel Cotton ball or gauze Bandage (optional) Sharps container (hard-walled container for discarding syringes) Note: GRANIX and all of the parts of the prefilled syringe do not contain natural rubber latex. 1B Take the carton with the syringe(s) out of the refrigerator 1C Check the label and the expiration date on the side of the carton Important: Do not inject if: “GRANIX ® (tbo-filgrastim)” is not listed on the carton. The expiration date on the syringe label has passed. 1D Remove the syringe(s) from the carton Open the carton by breaking the tamper proof seal and lifting the lid. Remove the number of syringes required for your daily dose by grasping each at the middle of the syringe body. After removing your required number of syringes, place the carton back in the refrigerator. 1E Look carefully at the syringe(s) and the medicine Hold the syringe body and check to make sure it is not damaged. Inspect the medicine in the syringe. GRANIX should be a clear liquid. Important: Do not inject if: GRANIX ® (tbo-filgrastim) is not listed on the syringe label. The medicine is cloudy, discolored, or foamy. The medicine contains lumps, flakes, or particles. 1F Wait 30 minutes for the syringe(s) to warm to room temperature Wait 30 minutes for GRANIX to naturally warm to room temperature. This will provide a more comfortable injection. 1G Wash your hands When ready to inject, wash your hands with soap and warm water and dry thoroughly with a clean towel. 1H Choose an injection site The recommended injection sites are: If you are self-injecting: Stomach-area (abdomen): Except for a 2-inch area around the navel (belly button). Thighs: Top or middle area of thighs. If a caregiver is injecting GRANIX for you: Arms: Fleshy areas on upper, back part of the arm. Upper hip or buttock: Fleshy areas around the back of the upper hips and upper sides of the buttocks. If 2 injections will be performed, then the second injection should be at least 1 inch away from the first injection. Do not inject into areas that are tender, red, bruised, hard, or have scars or stretch marks. Important: You should select a different injection site each time you give yourself an injection. If you want to use the same injection site for a dose requiring 2 injections, make sure the second injection site is at least 1 inch away from the first injection site. 1I Clean the injection site using an alcohol swab Allow site to dry for 5-10 seconds to avoid stinging. If giving 2 injections, then the distance between the 2 injection sites should be at least 1 inch apart. Do not touch or blow on site after cleaning. 2. Adjust medicine level for your prescribed dose 2A Remove the needle cap from the syringe Place a paper towel on the table. To remove the needle cap, hold the body of the syringe firmly with 1 hand (with the needle facing away from you). Pull the needle cap straight off, extending your hand away from the needle. Note: Throw away the needle cap in a sharps container. Do not recap the needle now or after the injection. 2B Hold the syringe upright and tap Hold the syringe upright (needle pointing up), as shown. Gently tap the barrel with your fingers to make sure any air bubbles rise to the top. 2C Slowly and carefully adjust the medicine level Hold the syringe with the needle pointing up and slightly away from you , as shown. Make sure you can easily see the syringe markings and numbers. Holding the plunger as shown, very slowly and carefully push the plunger up until the top edge of the grey rubber stopper is even with the line that corresponds to your prescribed dose. Note: If GRANIX gets on your skin, wash your skin with soap and water. If GRANIX get in your eyes, flush well with water. Note: If you accidentally removed too much GRANIX, contact your healthcare provider before giving your injection. 3. INJECT MEDICATION 3A Pinch skin Use your free hand to firmly pinch the skin you previously cleaned. 3B Insert the needle at a 45 to 90 degree angle Hold the body of the syringe between your thumb and index finger. Use a quick motion to fully insert the needle straight into the pinched skin at a 45 to 90 degree angle. When the needle is inserted, you can release the pinched skin. Do not hold or push on the plunger while inserting the needle into the skin. 3C Push the plunger down injecting all of the GRANIX Use your finger to gently push down on the plunger. When the plunger head is as far down as it will go, all of the GRANIX has been injected. When done, gently remove the needle from the skin. 3D Dispose of used syringe Put your used needles and syringes in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and syringes in your household trash. If you do not have a FDA-cleared sharps disposal container, you may use a household container that is: made of a heavy-duty plastic, can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, upright and stable during use, leak-resistant, and properly labeled to warn of hazardous waste inside the container. When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal. Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container. 3E Treat the injection site if needed and wash your hands If you see drops of blood at the injection site, you can press a cotton ball or gauze over the injection site for several seconds to stop the bleeding. Apply bandage, if needed. When you are finished, wash your hands with soap and warm water and dry thoroughly with a clean towel. 4. Repeat the procedure with the second syringe (If dose is more than 0.8mL) If your dose is more than 0.8mL: Follow instructions 3A through 3E for injecting. Choose a different site for your second injection. If you want to use the same part of your body, make sure the second injection site is at least 1 inch away from the first injection site. This Instructions for Use has been approved by the U.S. Food and Drug Administration. Manufactured by: UAB Teva Baltics Vilnius, Lithuania U.S. License No. 1803 Distributed by: Teva Pharmaceuticals USA, Inc. North Wales, PA 19454 Product of Israel Revised: 11/2019 TBOIFU-003 ©2014-2019 Cephalon, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. All rights reserved. GRANIX is a trademark of Teva Pharmaceutical Industries Ltd. ifu image 1 ifu image 2 ifu image 3 ifu image 4 ifu image 5 ifu image 6 ifu image 7 ifu image 8 ifu image 9 ifu image 10 ifu image 11 ifu image 12 ifu image 13 ifu image 14 ifu image 15 ifu image 16 ifu image 17 ifu image 18 ifu image 19 ifu image 20 ifu image 21 ifu image 22 ifu image 23 ifu image 24 ifu image 25 ifu image 26 ifu image 27 ifu image 28 ifu image 29 teva oncology logo 3

14 CLINICAL STUDIES The efficacy of GRANIX was evaluated in a multinational, multicenter, randomized and controlled Phase 3 study in 348 chemotherapy-naive patients with high-risk stage II, stage III, or stage IV breast cancer receiving doxorubicin (60 mg/m 2 ) and docetaxel (75 mg/m 2 ) comparing GRANIX to placebo and a non-US-approved filgrastim product as controls. The median age of the patients was 50 years (range 25 to75 years) with 99% female and 86% Caucasian. GRANIX, placebo, and the non-US-approved filgrastim product were administered at 5 mcg/kg subcutaneously once daily beginning one day after chemotherapy for at least five days and continued to a maximum of 14 days or until an ANC of ≥10,000 x 10 6 /L after nadir was reached. GRANIX was superior to placebo in duration of severe neutropenia (DSN) with a statistically significant reduction in DSN (1.1 days vs. 3.8 days, p < 0.0001).

8.5 Geriatric Use Among 677 cancer patients enrolled in clinical trials of GRANIX, a total of 111 patients were 65 years of age and older, and 14 patients were 75 years and older. No overall differences in safety or effectiveness were observed between patients age 65 and older and younger patients.

8.4 Pediatric Use The safety and effectiveness of GRANIX have been established for pediatric patients 1 month to < 17 years old (no data for the age group < 1 month old). Use of GRANIX in these age groups is supported by evidence from adequate and well-controlled studies of GRANIX in adults [see Clinical Studies (14)] with additional safety and pharmacokinetics data from a single-arm trial of 50 pediatric patients with solid tumors treated with GRANIX for chemotherapy-induced neutropenia. The 50 pediatric patients had a median age of 9.2 years (range, 1.4-15.9 years); 2 were infants (1 month to < 2 years old), 30 were children (2 to < 12 years old), and 18 were adolescents (12 to < 17 years old). The pharmacokinetics and safety profile of GRANIX in the pediatric population were similar to those seen in adults [see Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 )] .

8.1 Pregnancy Risk Summary The limited published data on filgrastim product use during pregnancy are insufficient to inform a drug-associated risk. In animal reproduction studies, administration of tbo-filgrastim to pregnant rabbits during organogenesis resulted in increased spontaneous abortion and fetal malformations at systemic exposures 50-90 times the human exposure expected at the recommended human dose (see Data) . GRANIX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In an embryofetal developmental study, pregnant rabbits were administered subcutaneous doses of tbo-filgrastim during the period of organogenesis at 1, 10 and 100 mcg/kg/day. Increased abortions were evident in rabbits treated with tbo-filgrastim at 100 mcg/kg/day. This dose was maternally toxic as demonstrated by reduced body weight. Other embryofetal findings at this dose level consisted of post-implantation loss‚ decrease in mean live litter size and fetal weight, and fetal malformations such as malformed hind limbs and cleft palate. The dose of 100 mcg/kg/day corresponds to a systemic exposure (AUC) of approximately 50-90 times the exposures observed in patients treated with the clinical tbo-filgrastim dose of 5 mcg/kg/day.

8 USE IN SPECIFIC POPULATIONS GRANIX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus ( 8.1 ) 8.1 Pregnancy Risk Summary The limited published data on filgrastim product use during pregnancy are insufficient to inform a drug-associated risk. In animal reproduction studies, administration of tbo-filgrastim to pregnant rabbits during organogenesis resulted in increased spontaneous abortion and fetal malformations at systemic exposures 50-90 times the human exposure expected at the recommended human dose (see Data) . GRANIX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In an embryofetal developmental study, pregnant rabbits were administered subcutaneous doses of tbo-filgrastim during the period of organogenesis at 1, 10 and 100 mcg/kg/day. Increased abortions were evident in rabbits treated with tbo-filgrastim at 100 mcg/kg/day. This dose was maternally toxic as demonstrated by reduced body weight. Other embryofetal findings at this dose level consisted of post-implantation loss‚ decrease in mean live litter size and fetal weight, and fetal malformations such as malformed hind limbs and cleft palate. The dose of 100 mcg/kg/day corresponds to a systemic exposure (AUC) of approximately 50-90 times the exposures observed in patients treated with the clinical tbo-filgrastim dose of 5 mcg/kg/day. 8.2 Lactation No data are available regarding the presence of tbo-filgrastim in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. Another filgrastim product was detected in human milk for up to 3 days after filgrastim administration. 8.4 Pediatric Use The safety and effectiveness of GRANIX have been established for pediatric patients 1 month to < 17 years old (no data for the age group < 1 month old). Use of GRANIX in these age groups is supported by evidence from adequate and well-controlled studies of GRANIX in adults [see Clinical Studies (14)] with additional safety and pharmacokinetics data from a single-arm trial of 50 pediatric patients with solid tumors treated with GRANIX for chemotherapy-induced neutropenia. The 50 pediatric patients had a median age of 9.2 years (range, 1.4-15.9 years); 2 were infants (1 month to < 2 years old), 30 were children (2 to < 12 years old), and 18 were adolescents (12 to < 17 years old). The pharmacokinetics and safety profile of GRANIX in the pediatric population were similar to those seen in adults [see Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 )] . 8.5 Geriatric Use Among 677 cancer patients enrolled in clinical trials of GRANIX, a total of 111 patients were 65 years of age and older, and 14 patients were 75 years and older. No overall differences in safety or effectiveness were observed between patients age 65 and older and younger patients.

16 HOW SUPPLIED/STORAGE AND HANDLING GRANIX solution for injection is supplied as a single-dose, preservative-free clear solution, in either a vial or, a prefilled syringe made from Type I glass which has a permanently attached stainless steel needle. The active substance is tbo-filgrastim. Prefilled Syringes (UltraSafe Passive ® Needle Guard) GRANIX 300 mcg/0.5 mL: Each prefilled syringe contains 300 mcg of tbo-filgrastim in 0.5 mL solution with a blue plunger in: Pack of 1 with a safety needle guard in blister: NDC 63459-910-11 Packs of 10 with a safety needle guard in blisters: NDC 63459-910-15 GRANIX 480 mcg/0.8 mL: Each prefilled syringe contains 480 mcg of tbo-filgrastim in 0.8 mL solution with a clear plunger in: Pack of 1 with a safety needle guard in blister: NDC 63459-912-11 Packs of 10 with a safety needle guard in blisters: NDC 63459-912-15 Prefilled Syringes GRANIX 300 mcg/0.5 mL: Each prefilled syringe contains 300 mcg of tbo-filgrastim in 0.5 mL solution with a blue plunger in: Pack of 1 without a safety needle guard (for patients and caregivers): NDC 63459-910-17 Packs of 5 without a safety needle guard (for patients and caregivers): NDC 63459-910-36 GRANIX 480 mcg/0.8 mL: Each prefilled syringe contains 480 mcg of tbo-filgrastim in 0.8 mL solution with a clear plunger in: Pack of 1 without a safety needle guard (for patients and caregivers): NDC 63459-912-17 Packs of 5 without a safety needle guard (for patients and caregivers): NDC 63459-912-36 Vials GRANIX 300 mcg/1 mL: Each vial contains 300 mcg of tbo-filgrastim in 1 mL solution. Packs of 10 single-dose vials: (NDC 63459-918-59) GRANIX 480 mcg/1.6 mL: Each vial contains 480 mcg of tbo-filgrastim in 1.6 mL solution. Packs of 10 single-dose vials: (NDC 63459-920-59) GRANIX and all its components are not made with natural rubber latex [see Dosage and Administration (2.2)] . Store GRANIX in a refrigerator at 36° to 46°F (2° to 8°C). Protect from light. Within its shelf life, the product may be removed from 36° to 46°F (2° to 8°C) storage for a single period of up to 5 days between 73° to 81°F (23° to 27°C). If not used within 5 days, the product may be returned to 36° to 46°F (2° to 8°C) up to the expiration date. Dispose of syringes if stored at room temperature for more than 5 days. Avoid shaking. The solution should be visually inspected prior to use. Only clear solutions without particles should be used. Exposure to 23° to 30°F (-1° to -5°C) for up to 72 hours and temperatures as low as 5° to -13°F (-15° to -25°C) for up to 24 hours do not adversely affect the stability of GRANIX. Single-dose syringe and single-dose vial – discard unused portion. Any unused product or waste material should be disposed of in accordance with local requirements. If GRANIX gets on the skin, wash the area with soap and water. If GRANIX gets in the eyes, thoroughly flush the exposed eye/eyes with water.